Mutations in the Plasmodium vivax multidrug resistance gene 1 (Pvmdr1) are associated with recurrence in vivax malaria after chloroquine/primaquine treatment in northeast Myanmar
Background: Plasmodium vivax malaria is a major challenge for malaria elimination in Southeast Asia. In many parts of the world, this parasite has developed resistance to the frontline treatment chloroquine, which led to the deployment of artemisinin combination therapies for vivax treatment. In northeast Myanmar, our earlier work detected a substantial proportion of the vivax cases developed asexual blood parasitemia within 28 days after chloroquine/primaquine treatment, suggesting that parasite’s sensitivity to chloroquine in this region is deteriorating. Here we investigated the potential mechanism of chloroquine resistance in vivax malaria by focusing on the pvmdr1 gene. Materials and Methods: We sequenced the complete Pvmdr1 gene from 18 recurrent parasites and 92 parasites from successfully treated cases. The presence and frequency of the mutations within this gene were compared. Results and Conclusions: A total of 11 and 12 mutations in the pvmdr1 gene were identified in the recurrent and successfully-treated cases. Comparison of their frequencies led to the identification of one mutation close to the C-terminus of this protein that was significantly more prevalent in recurrent cases. Further studies are needed to determine whether this mutation contribute to the chloroquine treatment failure.